Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Bristol-Myers Squibb(BMY) Zacks Investment Research·2024-04-26 00:50财务表现 - Bristol-Myers Squibb Company (BMY)报告的调整后每股亏损为4.40美元，比Zacks Consensus Estimate的每股亏损4.53美元要窄[1] - 总收入为119亿美元，超过了Zacks Consensus Estimate的114亿美元[3] - 美国收入增长7%，达到85亿美元，主要受益于Eliquis、Reblozyl和Opdualag的销售增长[4]